Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263747 | 0.84 | MCL1 (0.64) | MCL1ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL6317352 | 0.81 | MCL1 (0.64) | MCL1ALDH1A1L3MBTL1NPC1PKM | |
| SCHEMBL7025629 | 0.81 | MCL1 (0.64) | MCL1ALDH1A1L3MBTL1NPC1PKM | |
| SCHEMBL2263721 | 0.79 | MCL1 (0.62) | MCL1ALDH1A1SMN1; SMN2HPGDKDM4E | |
| SCHEMBL2268566 | 0.79 | MCL1 (0.70) | MCL1ALDH1A1HPGDPOLBKMT2A | |
| SCHEMBL2263200 | 0.79 | MCL1 (0.70) | MCL1ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL3437003 | 0.77 | ALDH1A1 (0.66) | MCL1CYP1A2CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL29249541 | 0.77 | MCL1 (0.72) | MCL1MEN1KMT2ATPSAB1 | |
| SCHEMBL2263105 | 0.76 | MCL1 (0.57) | MCL1CYP1A2CYP2C19ALDH1A1NPC1 | |
| SCHEMBL2264964 | 0.75 | MCL1 (0.70) | MCL1ALDH1A1RAB9ASMN1; SMN2PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | MCL1 3083/4885CYP1A2 162/4885CYP2C19 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.